HSS Journal

, Volume 4, Issue 2, pp 170–174 | Cite as

Von Willebrand Factor, Red Cell Fragmentation, and Disease Activity in Systemic Lupus Erythematosus

  • Rodolfo V. Curiel
  • Rajkumari Bhagati
  • Lakshmi Basavaraju
  • Delona Norton
  • James Katz
  • Elizabeth Haile
  • Arthur Weinstein
Original Article


This study sought to determine whether the plasma levels of Von Willebrand factor (vWf) and the degree of red blood cell (RBC) fragmentation on peripheral smear correlate with disease activity in systemic lupus erythematosus (SLE). Forty consecutive patients who fulfilled the criteria for SLE were studied prospectively for 1 year. Patients were categorized according to the SLE Disease Activity Index (SLEDAI) as either active (>2) or inactive disease and followed up monthly (active) or quarterly (inactive). At each visit, patients were examined fully and had complete blood count, tests on antibodies to double-stranded DNA, C3, and C4 levels, and urinalysis. Citrated plasma was analyzed for vWf antigen by standard enzyme-linked immunosorbent assay. A Wright’s stained blood smear was obtained and schistocytes were quantitated on blood smear. The number of schistocytes per 500 RBCs was determined and a schistocyte index (SI) was calculated. At baseline, vWf correlated with SLEDAI (r = 0.64, p < 0.01), SI correlated with SLEDAI (r = 0.62, p < 0.01), and vWf and SI correlated with each other (r = 0.41, p = 0.01). There was an inverse correlation between baseline C3 levels and vWf (r = 0.49, p = 0.0013) and C3 levels and SI (r = 0.40, p = 0.01). Over time, there was also a correlation of SLEDAI with vWf (r = 0.53, p = 0.002) and SI (r = 0.57;p = 0.002). The relation of vWf with SI approached but did not reach statistical significance (r = 0.37, p = 0.06). We found that the plasma levels of vWf and the degree of RBC fragmentation correlate with lupus disease activity over time. Therefore, inflammation in SLE may be associated with endothelial injury.


  1. 1.
    Cavazzana I, Pellegrini S, Salmaggi A (2003) Endothelium and the brain in CNS lupus. Lupus 12(12):919–928 doi:10.1191/0961203303lu503oa PubMedCrossRefGoogle Scholar
  2. 2.
    Clancy R, Marder G, Martin V, Belmont HM, Abramson SB, Buyon J (2001) Circulating activated endothelial cells in systemic lupus erythematosus: further evidence for diffuse vasculopathy. Arthritis Rheum 44(5):1203–1208PubMedCrossRefGoogle Scholar
  3. 3.
    Bridoux F, Vrtovsnik F, Noel C, Saunier P, Mougenot B, Lemaitre V, Dracon M, Lelievre G, Vanhille P (1998) Renal thrombotic microangiopathy in systemic lupus erythematosus: clinical correlations and long-term survival. Nephrol Dial Transplant 13(2):298–304 doi:10.1093/ndt/13.2.296 PubMedCrossRefGoogle Scholar
  4. 4.
    Mannucci PM, Vanoli M, Forza I, Canciani MT, Scorza R (2003) Von Willebrand factor cleaving protease (ADAMTS-13) in 123 patients with connective tissue diseases (systemic lupus erythematosus and systemic sclerosis). Haematologica 88(8):914–918PubMedGoogle Scholar
  5. 5.
    Manadan AM, Harris C, Schwartz MM, Block JA (2003) The frequency of thrombotic thrombocytopenic purpura in patients with systemic lupus erythematosus undergoing kidney biopsy. J Rheumatol 30(6):1227–1230PubMedGoogle Scholar
  6. 6.
    Vasoo S, Thumboo J, Fong KY (2002) Thrombotic thrombocytopenic purpura in systemic lupus erythematosus: disease activity and the use of cytotoxic drugs. Lupus 11(7):443–450 doi:10.1191/0961203302lu224oa PubMedCrossRefGoogle Scholar
  7. 7.
    Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, Crow MK, Schwartz JE, Paget SA, Devereux RB, Salmon JE (2003) Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. New Engl J Med 349:2399–2406 doi:10.1056/NEJMoa035471 PubMedCrossRefGoogle Scholar
  8. 8.
    Al-Herz A, Ensworth S, Shojania K, Esdaile JM (2003) Cardiovascular risk factor screening in systemic lupus erythematosus. J Rheumatol 30(3):493–496PubMedGoogle Scholar
  9. 9.
    Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, Cote R, Grover SA, Fortin PR, Clarke AE, Senécal JL (2001) Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 44(10):2331 doi:10.1002/1529-0131(200110)44:10<2331::AID-ART395>3.0.CO;2-I PubMedCrossRefGoogle Scholar
  10. 10.
    Panza JA (1994) Endothelium-dependent vasodilatation and essential hypertension. N Engl J Med 331(14):951PubMedCrossRefGoogle Scholar
  11. 11.
    Lima DS, Sato EI, Lima VC, Miranda F Jr, Hatta FH (2002) Brachial endothelial function is impaired in patients with systemic lupus erythematosus. J Rheumatol 29(2):292–297PubMedGoogle Scholar
  12. 12.
    Paleolog EM, Crossman DC, Mc Vey JH, Pearson JD (1990) Differential regulation by cytokines of constitutive and stimulated secretion of Von Willebrand factor from endothelial cells. Blood 75(3):688–695PubMedGoogle Scholar
  13. 13.
    Van Mourik JA, Boertjes R, Huisveld IA, Fijnvandraat K, Pajkrt D, Van Gendern PJ, Fijnheer R (1999) Von Willebrand factor propeptide in vascular disorders: a tool to distinguish between acute and chronic endothelial perturbation. Blood 94(1):179–185PubMedGoogle Scholar
  14. 14.
    Blann AD (2006) Plasma von Willebrand factor, thrombosis, and the endothelium: the first 30 years. Thromb Haemost 95(1):49–55PubMedGoogle Scholar
  15. 15.
    Ray KK, Morrow DA, Gibson CM, Murphy S, Antman EM, Braunwald E (2005) Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: an ENTIRE-TIMI 23 substudy. Eur Heart J 26(5):440–446 doi:10.1093/eurheartj/ehi104 PubMedCrossRefGoogle Scholar
  16. 16.
    Nadar SK, Al Yemeni E, Blann AD, Lip GY (2004) Thrombomodulin, von Willebrand factor and E-selectin as plasma markers of endothelial damage/dysfunction and activation in pregnancy induced hypertension. Thromb Res 113(2):123–128 doi:10.1016/j.thromres.2004.02.010 PubMedCrossRefGoogle Scholar
  17. 17.
    Cherian P, Hankey GJ, Eikelboom JW, Thom J, Baker RI, McQuillan A, Staton J, Yi Q (2003) Endothelial and platelet activation in acute ischemic stroke and its etiological subtypes. Stroke 34(9):2132–2137 doi:10.1161/01.STR.0000086466.32421.F4 PubMedCrossRefGoogle Scholar
  18. 18.
    Scheja A, Akesson A, Geborek P, Wildt M, Wollheim CB, Wollheim FA, Vischer UM (2001) Von Willebrand factor propeptide as a marker of disease activity in systemic sclerosis. Arthritis Res 3(3):178–182 doi:10.1186/ar295 PubMedCrossRefGoogle Scholar
  19. 19.
    Lopes AA, Maeda NY (1998) Circulating von Willebrand factor antigen as a predictor of short-term prognosis in pulmonary hypertension. Chest 114(5):1276–1282 doi:10.1378/chest.114.5.1276 PubMedCrossRefGoogle Scholar
  20. 20.
    Tan EM, Cohen AS, Fries JF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277 doi:10.1002/art.1780251101 PubMedCrossRefGoogle Scholar
  21. 21.
    Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35(6):630–640 doi:10.1002/art.1780350606 PubMedCrossRefGoogle Scholar
  22. 22.
    Rick ME, Moll S, Taylor MA, Krizek DM, White GC 2nd, Aronson DL (2002) Clinical use of a rapid collagen binding assay for von Willebrand factor cleaving protease in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 88(4):598–604PubMedGoogle Scholar
  23. 23.
    Moake JL (2002) Thrombotic microangiopathies. N Engl J Med 347(8):589–600 doi:10.1056/NEJMra020528 PubMedCrossRefGoogle Scholar
  24. 24.
    Rick ME, Austin H, Leitman SF, Krizek DM, Aronson DL (2004) Clinical usefulness of a functional assay for the von Willebrand factor cleaving protease (ADAMTS-13) and its inhibitor in a patient with thrombotic thrombocytopenic purpura. Am J Hematol 75(2):96–100 doi:10.1002/ajh.10457 PubMedCrossRefGoogle Scholar
  25. 25.
    Ibañez D, Gladman D, Urowitz M (2007) Summarizing disease features over time: II. Variability measures of SLEDAI-2K. J Rheumatol 34(2):336–340PubMedGoogle Scholar
  26. 26.
    Bastian HM, Vila LM, Wu R, Shoenfeld Y, Roseman JM, Reveille JD, LUMINA Study Group (2004) Systemic lupus erythematosus in a multiethnic US cohort (LUMINA).XXIII. Baseline predictors of vascular events. Arthritis Rheum 50(12):3947–3957 doi:10.1002/art.20622 PubMedCrossRefGoogle Scholar
  27. 27.
    Constans J, Dupuy R, Blann AD, Resplandy F, Seigneur M, Renard M, Longy-Boursier M, Schaeverbeke T, Guerin V, Boisseau MR, Conri C (2003) Anti-endothelial cell autoantibodies and soluble markers of endothelial cell dysfunction in systemic lupus erythematosus. J Rheumatol 30(9):1963–1966PubMedGoogle Scholar
  28. 28.
    Moscato S, Pratesi F, Bongiorni F, Scavuzzo MC, Chimenti D, Bombardieri S, Migliorini P (2002) Endothelial cell binding by systemic lupus antibodies: functional properties and relationship with anti-DNA activity. J Autoimmun 18(3):231–238 doi:10.1006/jaut.2002.0583 PubMedCrossRefGoogle Scholar
  29. 29.
    Yazici ZA, Raschi E, Patel A, Testoni C, Borghi MO, Graham AM, Meroni PL, Lindsey N (2001) Human monoclonal anti-endothelial cell IgG-derived from a systemic lupus erythematosus patient binds and activates human endothelium in vitro. Int Immunol 13(3):349–357 doi:10.1093/intimm/13.3.349 PubMedCrossRefGoogle Scholar
  30. 30.
    Bessant R, Hingorani A, Patel L, MacGregor A, Isenberg DA, Rahman A (2004) Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus. Rheumatology (Oxford) 43(7):924–929 doi:10.1093/rheumatology/keh213 CrossRefGoogle Scholar
  31. 31.
    Fischer LM, Schlienger RG, Matter C, Jick H, Meier CR (2004) Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of first-time acute myocardial infarction. Am J Cardiol 93(2):198–200PubMedCrossRefGoogle Scholar
  32. 32.
    Karrar A, Sequeira W, Block JA (2001) Coronary artery disease in systemic lupus erythematosus: a review of the literature. Semin Arthritis Rheum 30(6):436–43 doi:10.1053/sarh.2001.23498 PubMedCrossRefGoogle Scholar
  33. 33.
    Urowitz M, Gladman D, Bruce I (2000) Atherosclerosis and systemic lupus erythematosus. Curr Rheumatol Rep 2(1):19–23 doi:10.1007/s11926-996-0064-9 PubMedCrossRefGoogle Scholar

Copyright information

© Hospital for Special Surgery 2008

Authors and Affiliations

  • Rodolfo V. Curiel
    • 1
  • Rajkumari Bhagati
    • 1
  • Lakshmi Basavaraju
    • 1
  • Delona Norton
    • 1
  • James Katz
    • 1
  • Elizabeth Haile
    • 1
  • Arthur Weinstein
    • 2
  1. 1.Medical Faculty AssociatesThe George Washington UniversityWashingtonUSA
  2. 2.Washington Hospital CenterWashingtonUSA

Personalised recommendations